J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Journal Article
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Henry C. Pitot,Richard M. Goldberg,Joel M. Reid,Jeff A. Sloan,Pam Atherton Skaff,Charles Erlichman,Joseph Rubin,Patrick A. Burch,Alex A. Adjei,Steven A. Alberts,Larry J. Schaaf,Gary Elfring,Langdon L. Miller +12 more
TL;DR: Gastrointestinal toxicity and hematological toxicity were the dose-limiting toxicities of CPT-11 when administered as a 90-min infusion every 3 weeks when given on a once-every-3-week schedule.
Journal Article
Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
TL;DR: A sensitive, specific method for the determination of MTIC levels in plasma, based on reverse-phase high-pressure liquid chromatography of the supernatant that is obtained by methanol precipitation of plasma proteins, was developed.
Journal ArticleDOI
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Trent R. Hummel,Lars M. Wagner,Charlotte H. Ahern,Maryam Fouladi,Joel M. Reid,Renee M. McGovern,Matthew M. Ames,Richard J. Gilbertson,Terzah M. Horton,Ashish M. Ingle,Brenda J. Weigel,Susan M. Blaney +11 more
TL;DR: The maximum tolerated dose, dose‐limiting toxicities (DLT), and pharmacokinetic properties of vorinostat, a histone deacetylase (HDAC) inhibitor, when given in combination with temozolomide in children with refractory or recurrent CNS malignancies are estimated.
Journal ArticleDOI
Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Shiv K. Gupta,Ann C. Mladek,Brett L. Carlson,Felix Boakye-Agyeman,Katrina K. Bakken,Sani H. Kizilbash,Mark A. Schroeder,Joel M. Reid,Jann N. Sarkaria +8 more
TL;DR: In vitro cytotoxicity assays do not adequately model the therapeutic index of PARP inhibitors, as concentrations of veliparib and TMZ required to sensitize TMZ-resistant cancer cells in vivo cannot be achieved using a tolerable dosing regimen.
Journal ArticleDOI
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study
Rani E. George,Jill M. Lahti,Peter C. Adamson,Kejin Zhu,David Finkelstein,A. Mark Ingle,Joel M. Reid,Mark Krailo,Donna Neuberg,Susan M. Blaney,Lisa Diller +10 more
TL;DR: A phase I trial was conducted to determine the toxicity and molecular effects of the demethylating agent, decitabine, followed by doxorubicin and cyclophosphamide in children with refractory solid tumors.